49 results about "Uncoupling protein" patented technology

The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of or the making of medicaments for the treatment of metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia.

The invention discloses new application of axitinib. Axitinib can be used for preparing medicine for promoting white fat cell browning and used for preventing and treating obesity and diseases related to obesity. The medicine can promote primary white fat cell browning in vitro, thereby enhancing expression of brown fat cell marker gene uncoupling protein 1 (UCP1), and can promote the increase of beige fat cells in white fat tissue of groin and the increase of expression of UCP1; the medicine can resist obesity and insulin insensitivity caused by high-fat diet and has an effect on treating fatty livers.

The invention discloses a non-human mammal model with an input UCP1-1cuiferase (uncoupling protein 1-1cuiferase) gene as well as a construction method and the application of the non-human mammal model. The constructed non-human mammal model with the input UCP1-1cuiferase gene can be taken as a screening platform of white fat cell brownness drugs, and the simple, rapid and large-scale screening on drugs for regulating and controlling the expression of the UCP1 can be realized; on the premise that non-human mammal is not hurt, the expression and distribution of the UCP1 can be directly subjected to bio-assay by utilizing a fluorescent imager.

A nucleotide sequence of hog uncoupling protein gene 2 and the method for testing its polymorphism are disclosed. Said nucleotide sequence, SEQ ID No.3, can code the hog UCP2 protein, is the sequence in the segment 3-4 of hog UCP2 exon and the segment 3 of intron, and has 89% homology with the nucleotide sequence of human relative sequence. It can be used to research the growth and energy conversion of hog.

The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-α (Pgd1α) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.

The invention discloses methods and compositions involving development of novel polymer-based therapeutics that induce browning of white adipocytes for the treatment of obesity and its associated metabolic diseases. The therapeutic effects are largely attributed to the promotion of brown and/or beige adipocyte development and function by leveraging adipocyte plasticity and polymer-based drug delivery systems. Both brown and beige adipocytes are densely packed with mitochondria which highly express uncoupling protein-1 (UCP1), a thermogenic protein mediating non-shivering thermogenesis.

The invention discloses a method for constructing a genetic engineering cell strain of an obesity-resistant medicine target point UCP1, and besides, discloses establishing and application of an obesity-resistant medicine high-flux screening model. Mainly a CRISPR/Cas9 system is related and utilized, two unique sgRNAs are designed, luciferase-T2A-tdTomato-WPRE-pA is knocked in after N end ATG of aUCP1 gene of cells, particularly luciferase and tdTomato are knocked in gene sites of immortalization brown fat cells UCP1, a first stably-transfected brown fat cell strain in which luciferase and tdTomato are inserted in a promoter region of the UCP1 is formed, and the first stably-transfected brown fat cell strain is applied to high-flux screening of obesity-resistant medicines, evaluation of the obesity-resistant medicines, evaluation of obesity-resistant active substances of organisms and development of a UCP1 detection reagent kit. The UCP1 is uncoupling protein specifically expressed atbrown fat tissue, and is an obesity-resistant new target point. The construction of the stably-transfected genetic engineering cell strain has important significance in the aspects of applying reportgenes and a high-connotation method, performing high-flux screening on a compound library acutely, accurately and efficiently, and obtaining obesity-resistant medicines capable of promoting thermogenesis and reducing weight.

The invention relates to an amphioxus uncoupling protein (UCP) molecule clone and the functional research in the biotechnology field. The invention clones uncoupling protein (UCP) gene from amphioxus firstly with degeneracy primer and 3', 5'-RACE, which expresses muscle, intestinal canal and gill widely. Heightening UCP expression on the third day with dealing in low temperature indicates UCP engaging in body heat regulation in low temperature; Reducing UCP expression with hungry for fourteen days indicates that UCP engages in energy metabolism regulation. UCP is related to many diseases as diabetes, cardiovascular disease, tumour and so on, so UCP can be produced medicines treating these diseases.

The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.

This invention relates to molecular cloning of uncoupling protein (UCP) of Lampetra japonica. The UCP gene is cloned from Lampetra japonica with degenerate primer through 3',5'-RACE. UCP gene is associated with serveral diseases, such as diabetes mellitus, cardiovascular diseases and tumors. UCP gene can be used as a drug target for manufacturing drugs for treating above diseases.

The present invention concerns the design of a method for determining the activity of UCPs and which method can be used to evaluate the ability of different drugs to modify the activity of said proteins. These drugs may be used in the treatment of all diseases and conditions in which changes in thermogenic activity occur. Examples of these are obesity, fever, cachexia etc. Since the activity of the UCPs produces changes in the respiration rate, in the present method the activity of the UCPs is determined by monitoring the disappearance of NADH or NAD(P)H from the reduction in absorption between 300 and 380 nm or in fluorescence from 420-520 nm. In this method, these coenzymes are oxidised by the mitochondria of the yeast Saccharomyces cerevisiae in which different UCPs are expressed in a recombinant manner.

The invention provides novel application of Linifanib. The Linifanib has the functions of promoting browning of white adipocytes, promoting the expression of an uncoupling protein 1 (Ucp1), promotingmRNA expression levels of browning marker genes PrDm16, Pgcl alpha, Cidea, Dio2 and Cox8b, inhibiting preadipocytes to be differentiated into adipocytes and remarkably inhibiting the adipocytes to generate mRNA expressions of marker genes Ppar gamma, Cebp alpha and Ap2. Therefore, the Linifanib has the functions of promoting the browning of the adipocytes and inhibiting generation of the adipocytes, so that the Linifanib plays an important role in preventing and treating diseases related to fat metabolism and has a great application prospect in prevention and development of drugs of adiposis,diabetes mellitus, fatty liver and hyperlipidaemia.

The invention discloses a preparation method of rabbit anti-tree shew antiserum. The method comprises the steps of selecting an experimental animal, preparing serum, carrying out primary immunization and booster immunization and testing serum titer; the preparation method of the serum comprises the steps of collecting blood, stopping bleeding, preparing the serum and comparing the function of the serum; a bidirectional immune diffusion method is adopted by the test for the serum titer. According to the preparation method of the rabbit anti-tree shew antiserum, the content of tree shew uncoupling protein-1(UCP1) can be measured by the prepared antiserum, and the result error is generally within the range of 3-5%, so that the error range is reduced; after the steps of primary immunization and booster immunization are utilized, the production cost is lowered, the UCP1 content measurement effect is good, and the economic benefit is high.

A method using the extrat of capejasmine fruit to specifically suppress the uncoupling protein 2 (UCP 2) for improving the secretion of insulin and treating diabetes B includes such steps as decocting capejasmine fruit, extracting by macroreticular resin, diluting with alcohol, vacuum freeze-drying to obtain extract, and using it to culture the pancreatic island cells of mouse for obviously stimulating the secretion of insulin.

The invention discloses an application of UCP1 (uncoupling protein 1) to activity detection of human recombinant FGF21 (fibroblast growth factor 21) protein. Adipocytes subjected to induced differentiation are taken as objects, qRT-PCR (quantitative real-time polymerase chain reaction) is adopted to detect the rising degree of UCP1 gene expression level of the adipocytes processed by the human recombinant FGF21 protein with different concentrations, and the activity of the human recombinant FGF21 protein is determined. The invention discovers that the UCP1 expression level and the concentration of the used human recombinant FGF21 protein have a good dose-effect relationship, so that the UCP1 expression level of the adipocytes is determined to be a new index for activity detection of the human recombinant FGF21 protein. A method adopts a simple operation process, has low environmental requirement and has good practical value.